Basel, Switzerland – September 23, 2025 – metaLead Therapeutics AG (“metaLead”) announces the appointment of David Urech, PhD, Founder and former Chief Executive Officer of Numab Therapeutics AG, as an independent member of its Board of Directors.
”We are thrilled to have David join our board. He brings tremendous experience and an unparalleled track record of success that is reserved for only a few in our industry. David built Numab into a powerful, innovative company that creates value for patients and shareholders alike. I am excited about this opportunity to learn from and collaborate with David in guiding metaLead towards a bright future.
Michal Shoshan, PHDFounder and Chief Executive Officer at metaLead
Vincent Forster, PhD, who has served on metaLead’s Board of Directors since its incorporation, will step down to dedicate his time to his new venture, Nerai Bioscience. Vincent was instrumental in shaping metaLead’s early development, drawing on his prior success with Versantis to help establish a strong foundation for the company. The Board thanks Vincent for his invaluable contributions and wishes him and Nerai continued success.
”I am excited to join the board of metaLead to support the vision to bring innovative therapies with breakthrough potential to patients suffering from severe metal-induced conditions. Michal impressed me with a clear strategy that is based on expertise and business acumen.
David UrechBoard Member at metaLead
About metaLead Therapeutics AG
metaLead is a Swiss biotech company spun out of the University of Zurich, pioneering a new era of metal-centered medicine. The company has developed a novel metal-binding peptide platform to create best-in-class therapeutics that target pathological metals, restore healthy balance, or deliver therapeutic counterparts. While building a pipeline across multiple indications, metaLead’s lead program focuses on Wilson disease, a genetic disorder caused by copper overload, with the aim of delivering a safer and more effective treatment for patients worldwide.
metaLead has been supported by the UZH Life Sciences Fund (backed by Novartis Venture Fund), BaseLaunch, the BioInnovation Institute (BII), KickFund, Venture Kick, and Innosuisse. For more information, visit: www.metalead.ch
